On December 2, 2019 Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, reported an oral presentation at the 61st Annual American Society of Hematology (ASH) (Free ASH Whitepaper) meeting being held December 7-10, 2019 in Orlando, Florida (Press release, Cellectar Biosciences, DEC 2, 2019, View Source [SID1234551916]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Presentation details:
Present Title: Fractionated Dosing of CLR 131 in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)
Presenting Author: Dr. Sikander Ailawadhi
Session: 653. Myeloma: Therapy, excluding Transplantation: New Approaches in the Treatment of Relapsed/Refractory Plasma Cell Discrasias
Date/Time: Saturday, December 7, 2019 / 9:30 am – 11:00 am
Location: Orange County Convention Center, Hall E1
A copy of the poster can be accessed on the Posters and Publications section of the Cellectar website on the day of the poster presentation.